Answers are grounded in this paper and cite their sources.
Previous findings of our and other groups revealed that early TCA represents a rational therapeutic target for trauma patients. Nomacopan as a pro-survival and organ-protective drug, could emerge as a promising adjunct to DCR that may significantly reduce the morbidity and mortality in severe TH patients while awaiting transport to critical care facilities.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: